Burden of severe RSV disease among immunocompromised children and adults: a 10 year retrospective study
- PMID: 29510663
- PMCID: PMC5838875
- DOI: 10.1186/s12879-018-3002-3
Burden of severe RSV disease among immunocompromised children and adults: a 10 year retrospective study
Abstract
Background: Respiratory syncytial virus (RSV) is associated with significant mortality rates amongst hematopoietic stem cell transplant (HSCT) recipients, with less known about other immunocompromised patients.
Methods: Ten-year retrospective cohort study of immunocompromised patients presenting with RSV disease documented at University Hospitals of Lausanne and Geneva. Severe RSV-related outcomes referred to RSV documented respiratory conditions requiring hospital admission, presenting as lower respiratory tract infection (LRTI) or pneumonia. We used multivariable logistic regression to assess clinical and laboratory correlates of severe RSV disease.
Results: From 239 RSV-positive immunocompromised in and out-patients 175 were adults and 64 children of whom 111 (47.8%) presented with LRTI, which resulted in a 38% (89/239) admission rate to hospital. While immunocompromised children were more likely to be admitted to hospital compared to adults (75% vs 62.9%, p = 0.090), inpatients admitted to the intensive care unit (17/19) or those who died (11/11) were mainly adults. From multivariable analyses, adults with solid tumors (OR 5.2; 95% CI: 1.4-20.9 P = 0.015) or those requiring chronic immunosuppressive treatments mainly for rheumatologic conditions (OR 4.1; 95% CI: 1.1-16.0; P = 0.034) were significantly more likely to be admitted to hospital compared to hematopoietic stem cell (HSCT) recipients. Bacterial co-infection was significantly and consistently associated with viral LRTI and pneumonia.
Conclusions: From our findings, RSV-related disease results in a significant burden among adults requiring chronic immunosuppressive treatments for rheumatological conditions and those with solid tumors. As such, systematic screening for respiratory viruses, should be extended to other immunocompromised populations than HSCT recipients.
Conflict of interest statement
Ethics approval and consent to participate
The local ethics committees (REB) of Lausanne (CER-VD 86/15) and Geneva (CCER GE 15–085) approved this study and they waived the requirement for obtaining informed consent.
Consent for publication
Not applicable.
Competing interests
Olga Chatzis, Stephanie Darbre, Jerôme Pasquier, Pascal Meylan, Oriol Manuel, John David Aubert, Maja Beck-Popovic, Stavroula Masouridi-Levrat, Marc Ansari, Laurent Kaiser MD and Klara M. Posfay-Barbe have no conflicts of interest to declare. Sandra A. Asner received an educational Grant from Abbvie Switzerland.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
References
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases
Research Materials